Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Favipiravir compared to Arbidol in COVID-19 patients

Trial Profile

A clinical study of Favipiravir compared to Arbidol in COVID-19 patients

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2020

At a glance

  • Drugs Favipiravir (Primary) ; Umifenovir
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Mar 2020 New trial record
    • 19 Mar 2020 Results(n=240) published in the Zhejiang Hisun Pharmaceutical Media Release.

Trial Overview

Purpose

This study will evaluate Favipiravir compared to Arbidol in COVID-19 patients.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations Zhejiang Hisun Pharmaceutical

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase III
  • Location China
  • Focus Adverse reactions; Therapeutic Use

Interventions

Drugs Route Formulation
FavipiravirPrimary Drug Oral Tablet
Umifenovir
-
-

Results

Therapeutic efficacy

In a clinical trial in patients with COVID-2019 infections, significant clinical differences were observed between the 35-patient experimental group treated with favipiravir and the 45-patient control group treated with lopinavir/ritonavir. The medians of the virus clearance time were 4 days (2.5 ~ 9 days) and 11 days (8 ~ 13 days), respectively (P < 0.001); the posttreatment fever-allaying rates within 2 days were 72.41% versus 26.30%; while the chest-imaging improvement rates were 91.43% versus 62.22% [1] .

Results from a clinical trial in patients with COVID-2019 infections demonstrated that effectiveness was better in the patients treated with favipiravir than control group patients treated with abidole and was 71.43% and 55.86%, respectively. The same effects were obderved for the average antipyretic and cough remission time [1] .

Adverse events

Clinical:
In a clinical trial in patients with COVID-2019 infections, the rate of adverse reaction in favipiravir-treated patients was 11.43% and in dontrol group treated with lopinavir/ritonavir was 55.56% [1] .

Publications

  1. Zhejiang Hisun Pharmaceutical. Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients. Media-Rel 2020;.

    Media Release

Authors

Author Total Publications First Author Last Author
Zhejiang Hisun Pharmaceutical 1 1 1

Trial Centres

Centres

Centre Name Location Trial Centre Country
Zhongnan Hospital Wuhan China

Trial History

Event Date Event Type Comment
24 Mar 2020 New trial record New trial record Updated 24 Mar 2020
19 Mar 2020 Results Results(n=240) published in the Zhejiang Hisun Pharmaceutical Media Release. Updated 24 Mar 2020

References

  1. Zhejiang Hisun Pharmaceutical. Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients. Media-Rel 2020;.

    Media Release
Back to top